AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today ...
Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...
News-Medical.Net on MSN
New evidence supports ablation for high-risk patients with AFib and sleep apnea
Obstructive sleep apnea and atrial fibrillation are two conditions that share a potentially deadly link. Having one increases ...
AtriCure announced the successful first-in-human AFib treatments using its novel dual-energy surgical cardiac ablation platform.
Obstructive sleep apnea and atrial fibrillation (AFib) are two conditions that share a potentially deadly link. Having one ...
Boston Scientific (NYSE: BSX) announced recently that it received CE mark for its Farapoint pulsed field ablation (PFA) ...
Obstructive sleep apnea is associated with increased atrial fibrillation recurrence after ablation in patients with paroxysmal atrial fibrillation.
Boston Scientific has obtained an approval in Europe for the latest addition to its pulsed field ablation portfolio, with the ...
A next-generation treatment for atrial fibrillation that uses real-time 3D imaging to precisely visualize the heart's structure has been successfully performed. This latest pulsed field ablation techn ...
Intracardiac echocardiography is noninferior to TEE for prevention of thromboembolic complications in patients receiving ablation for AF.
Imricor has completed the world’s first ischemic ventricular tachycardia ablation procedure under MRI. CEO Steve Wedan has bigger plans ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback